Loading
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Previous close
$0.29
+$0.059 · +25.54%
Pre-market
$0.3022
+$0.0122 · +4.21%
Sep 11, 7:18 AM ET
Regular session · ET · Market data may be delayed.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Day range
Current $0.29
52-week range
Current $0.29
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
60
Fair Value
Sentiment
51
Mixed
Risk
71
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Day range
Current $0.29
52-week range
Current $0.29
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 4.09M USD | 14.18M USD | 33.05M USD | 34.75M USD | 25.73M USD |
| Selling, general, and administrative | 12.21M USD | 13.64M USD | 19.79M USD | 13.68M USD | 11.15M USD |
| Operating expenses | 12.8M USD | −72.99M USD | 348.09M USD | 48.43M USD | 65.85M USD |
| Depreciation and amortization | 78K USD | 97K USD | 99K USD | 68K USD | 3K USD |
| Operating income | −12.8M USD | 72.99M USD | −348.09M USD | −48.43M USD | −65.85M USD |
| Net income | −39.22M USD | 42.01M USD | −384.63M USD | −52.56M USD | −55.64M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Emerging Markets ETFSPEM
State Street SPDR S&P Emerging Markets Small Cap ETFEWX
Vanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
